Does ACV Lower Blood Sugar? Evidence Explained

Does ACV lower blood sugar? Apple cider vinegar has attracted considerable interest as a natural aid for blood glucose management, but the evidence behind the headlines is more nuanced than many sources suggest. Acetic acid, the active component in ACV, may produce modest reductions in post-meal blood glucose by slowing gastric emptying and potentially improving insulin sensitivity. However, the research is limited in scale and quality, and ACV is not recognised by the NHS or NICE as a treatment for diabetes or prediabetes. This article examines what the evidence actually shows, who should exercise caution, and what UK-recommended options are available.

Does apple cider vinegar actually lower blood sugar levels?

ACV can produce modest, short-term reductions in post-meal blood glucose via acetic acid, which slows gastric emptying, but it is not a medicine and should not replace prescribed diabetes treatment.

Apple cider vinegar (ACV) can produce modest, short-term reductions in blood glucose levels after meals, but it is not a clinically proven treatment for diabetes or blood sugar disorders. ACV is made by fermenting crushed apples, producing acetic acid as its primary active component. Researchers believe acetic acid may influence glucose metabolism, though the effect is relatively small and inconsistent across studies.

The proposed mechanism centres on acetic acid's ability to slow gastric emptying, meaning food moves more slowly from the stomach into the small intestine. This slows the absorption of carbohydrates and may blunt the post-meal rise in blood glucose, sometimes called the glycaemic spike. Some research also suggests acetic acid may improve insulin sensitivity in muscle cells, though this has been demonstrated more clearly in animal studies than in robust human trials.^[2] The degree of uncertainty around both mechanisms should be noted: human evidence remains limited.

It is important to understand that any blood glucose effect observed with ACV is modest and should not be compared to the action of prescribed glucose-lowering medicines. ACV is a food product, not a medicine, and it has not been authorised by the MHRA for any therapeutic indication.^[14] People who have been diagnosed with type 2 diabetes or prediabetes should not use ACV as a substitute for medical advice or prescribed treatment.

What does the current evidence say about ACV and glucose control?

Current evidence is limited, mixed in quality, and insufficient for NICE to recommend ACV; no large-scale randomised controlled trial has definitively established it as an effective glycaemic intervention.

The current evidence on ACV and blood glucose control is limited, mixed in quality, and insufficient to support firm clinical recommendations. Most published studies are small, short in duration, and vary considerably in the dose of ACV used, the population studied, and the outcomes measured.

A frequently cited study published in Diabetes Care (Johnston CS et al., 2004) found that consuming vinegar before a high-carbohydrate meal reduced post-meal blood glucose and insulin responses in people with insulin resistance and type 2 diabetes. However, the sample sizes were very small, limiting the generalisability of the findings.

A 2021 systematic review and meta-analysis published in the Journal of the Academy of Nutrition and Dietetics examined multiple trials and found that vinegar consumption was associated with statistically significant reductions in fasting blood glucose and HbA1c over periods of eight to twelve weeks. However, the authors noted that the included studies were heterogeneous and at risk of bias, limiting the strength of conclusions that can be drawn. Readers should be aware that further systematic reviews may have been published since 2021, and the evidence base continues to evolve.

There is currently no high-quality, large-scale randomised controlled trial that definitively establishes ACV as an effective intervention for glycaemic control in humans. The evidence base is promising enough to warrant further research, but it does not yet meet the standard required for NICE to recommend ACV as part of diabetes management pathways. Patients should treat media claims about ACV with appropriate scepticism and discuss any complementary approaches with their GP or diabetes care team.

Who might benefit from ACV, and who should be cautious?

People with prediabetes or mild insulin resistance may see a small benefit, but those with gastroparesis, kidney disease, oesophageal problems, or who take insulin or sulphonylureas should consult their GP first.

People with prediabetes or mild insulin resistance who are already following a balanced diet and lifestyle programme may find that ACV offers a small additional benefit in managing post-meal glucose levels, though this should always be discussed with a healthcare professional first. Some individuals who consume ACV as part of a salad dressing or diluted in water before meals report feeling fuller for longer, which may indirectly support weight management and glycaemic control.

However, several groups should exercise particular caution:

• People with gastroparesis (delayed gastric emptying, which can occur in long-standing diabetes): ACV may worsen this condition by further slowing stomach emptying, potentially causing nausea, bloating and unpredictable blood glucose patterns. Anyone with known or suspected gastroparesis should seek advice from their diabetes care team before using ACV.

• People taking insulin or sulphonylureas: any additional glucose-lowering effect, however modest, could theoretically increase the risk of hypoglycaemia. A GP or diabetes nurse should be consulted before adding ACV regularly to the diet. Do not adjust insulin or sulphonylurea doses without clinician advice.

• People with chronic kidney disease: high acid intake may place additional strain on kidneys already under stress. This caution is precautionary, as robust evidence specific to ACV in this group is lacking; discuss with your GP or renal team.

• People with a history of oesophageal problems or acid reflux: undiluted ACV is highly acidic and can irritate or damage the oesophageal lining.

• Pregnant or breastfeeding individuals: there is insufficient evidence on safety in these groups, and caution is advised.

Children and young people should not use ACV as a health supplement without specific medical guidance. Anyone unsure whether ACV is appropriate for their circumstances should speak to their GP before starting regular use.

How safe is it to take apple cider vinegar every day?

Daily diluted ACV is generally safe for healthy adults in small amounts, but carries documented risks including dental erosion, oesophageal irritation, hypokalaemia, and interactions with several medicines.

Daily consumption of apple cider vinegar is generally considered safe for most healthy adults when taken in small, diluted amounts, but regular use carries several well-documented risks that are often underreported in popular media.

The most consistent concern is dental erosion: ACV has a pH of approximately 2 to 3, making it highly acidic, and direct contact with tooth enamel over time can cause significant and irreversible damage.^[6] Drinking ACV through a straw and rinsing the mouth with water afterwards are commonly recommended precautions; NHS oral health guidance advises avoiding acidic drinks in contact with teeth where possible.

Oesophageal irritation is another recognised risk, particularly when ACV is consumed undiluted. Published case reports have described oesophageal injury following ACV tablet use, and the liquid form should always be diluted well in water before consumption.^[5] Studies investigating glycaemic effects have typically used one to two tablespoons (approximately 15 to 30 ml) per day, diluted in water; these figures reflect amounts used in research and do not constitute an established safe dose. If you are unsure how much to use, seek advice from a pharmacist or GP.

Long-term daily use at higher quantities has been associated with low potassium levels (hypokalaemia) and reduced bone mineral density in at least one case report, though this evidence is very limited and case reports cannot establish causality.^[7] ACV can also interact with certain medicines, including diuretics, digoxin and insulin, by affecting potassium levels or enhancing glucose-lowering effects. If you take any regular medicines, check with your GP or pharmacist before using ACV regularly.

If you experience persistent digestive discomfort, tooth sensitivity, or any unexpected symptoms after starting ACV, contact your GP. Suspected adverse reactions to food supplements can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

What do NHS guidelines say about diet and blood sugar management?

NHS and NICE guidelines do not include ACV in any dietary advice for blood sugar management, instead recommending reduced refined carbohydrates, increased fibre, healthy weight maintenance, and regular physical activity.

NHS guidelines, informed by NICE recommendations, do not include apple cider vinegar as part of any dietary advice for blood sugar management. Instead, NICE guidance on type 2 diabetes (NG28) and prediabetes emphasises evidence-based dietary and lifestyle interventions as the foundation of glycaemic control. These include reducing intake of refined carbohydrates and free sugars, increasing dietary fibre, maintaining a healthy body weight, and engaging in regular physical activity.

The NHS Diabetes Prevention Programme (NHS DPP) offers structured support for people identified as being at high risk of developing type 2 diabetes, including personalised dietary advice, physical activity coaching, and psychological support. Referral is typically made through a GP following a blood test showing a raised HbA1c (in the range of 42 to 47 mmol/mol) or raised fasting glucose levels consistent with prediabetes.

For people already living with type 2 diabetes, NICE recommends an individualised approach to diet, which may include low-carbohydrate eating patterns, Mediterranean-style diets, or total diet replacement programmes under medical supervision. None of these pathways include ACV as a recommended component. The NHS Eatwell Guide provides general population-level dietary advice that supports stable blood glucose through balanced meals, regular eating patterns, and limiting foods high in fat, salt and sugar, as well as limiting sugary drinks.

Patients are encouraged to work with their GP, practice nurse or a registered dietitian when making significant dietary changes, particularly if they are taking glucose-lowering medicines. Self-managing blood sugar through unproven supplements without professional oversight carries risks that outweigh any potential modest benefit.

Are there more effective ways to manage blood sugar in the UK?

NICE recommends lifestyle interventions, weight loss, and licensed medicines such as metformin, SGLT-2 inhibitors and GLP-1 receptor agonists as considerably more effective options than ACV for blood sugar management.

There are several well-evidenced, NICE-recommended approaches to managing blood sugar that are considerably more effective than apple cider vinegar for people with prediabetes or type 2 diabetes. Lifestyle interventions remain the most powerful first-line tools: sustained weight loss of 5% or more of body weight has been shown to significantly improve insulin sensitivity and HbA1c.^[11][12] Total diet replacement programmes have the strongest UK evidence for achieving remission of type 2 diabetes in some individuals, as demonstrated by the DiRECT trial (Lean et al., Lancet, 2018). Low-carbohydrate dietary approaches may also support glycaemic improvement, though the remission evidence for these is less robust than for total diet replacement.

Where lifestyle changes alone are insufficient, NICE (NG28) recommends a range of licensed glucose-lowering medicines. Metformin remains the first-line pharmacological option for most people with type 2 diabetes. For those requiring additional glucose control or who have cardiovascular or renal comorbidities, NICE recommends SGLT-2 inhibitors (such as empagliflozin or dapagliflozin) and GLP-1 receptor agonists (such as semaglutide, available as Ozempic for type 2 diabetes). Tirzepatide (Mounjaro) is authorised by the MHRA both for type 2 diabetes and for chronic weight management in adults meeting specific criteria.^[8]

For people exploring medically supervised weight management as a route to better blood sugar control, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online consultations, with prescriber review and pharmacist support, where a range of options may be considered if clinically appropriate.

Blood glucose monitoring, regular HbA1c testing, and structured education programmes such as DESMOND and X-PERT are also recommended by NICE to support self-management; availability of specific programmes varies by locality. Anyone concerned about their blood sugar levels should contact their GP in the first instance, rather than relying on dietary supplements.

If you experience symptoms of severe hypoglycaemia, including confusion, seizures or loss of consciousness, call 999 immediately. For urgent but non-emergency concerns about hypoglycaemia or hyperglycaemia, contact NHS 111.

Scientific References

1. Delayed gastric emptying rate may explain improved glycaemia in healthy subjects to a starchy meal with added vinegar.
2. Vinegar improves insulin sensitivity to a high-carbohydrate meal in subjects with insulin resistance or type 2 diabetes.
3. Effect of apple cider vinegar on delayed gastric emptying in patients with type 1 diabetes mellitus.
4. Effect of Dietary Acetic Acid Supplementation on Plasma Glucose, Lipid Profiles, and Body Mass Index in Human Adults: A Systematic Review and Meta-analysis.
5. Esophageal injury by apple cider vinegar tablets and subsequent evaluation of products.
6. Evidence That Daily Vinegar Ingestion May Contribute to Erosive Tooth Wear in Adults.
7. Hypokalemia, hyperreninemia and osteoporosis in a patient ingesting large amounts of cider vinegar.
8. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
9. Type 2 diabetes in adults: management (NG28).
10. Type 2 diabetes in adults: management (NG28) — Initial medicines chapter.
11. Overweight and obesity in adults.
12. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.
13. 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT).
14. Guidance on new provisions for traditional herbal medicinal products and homoeopathic medicinal products.
15. Type 2 diabetes: prevention in people at high risk (PH38).

Frequently Asked Questions